Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apogee Therapeutics (APGE) Depreciation & Amortization (CF) (2024 - 2026)

Apogee Therapeutics (APGE) reported Depreciation & Amortization (CF) of $400000.0 for Q1 2026, up 100.0% year-over-year from $200000.0 in Q1 2025, and down 1.48% on a QoQ basis from $406000.0 in Q4 2025.

Apogee Therapeutics (APGE) has 3 years of Depreciation & Amortization (CF) data on file, last reported at $400000.0 in Q1 2026.

  • Quarterly Depreciation & Amortization (CF) rose 100.0% year-over-year to $400000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (up 318.23% YoY) and the FY2025 annual result came in at $1.4 million, up 609.0% from the prior year.
  • Depreciation & Amortization (CF) eased to $400000.0 in Q1 2026 per APGE's latest filing, from $406000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $406000.0 in Q4 2025 and bottomed at $29000.0 in Q1 2024.
  • The 3-year median for Depreciation & Amortization (CF) is $200000.0 (2025), against an average of $224333.3.
  • The widest annual swing landed in 2025, when Depreciation & Amortization (CF) soared 1011.11%; it then surged 100.0% in 2026.
  • Tracing APGE's Depreciation & Amortization (CF) over 3 years: stood at $100000.0 in 2024, then soared by 306.0% to $406000.0 in 2025, then fell by 1.48% to $400000.0 in 2026.
  • Per Business Quant, the three latest APGE Depreciation & Amortization (CF) figures stand at $400000.0 (Q1 2026), $406000.0 (Q4 2025), and $400000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 1,395.22
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 55.90 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 123.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 13.55 Mn
10 Apogee Therapeutics 5.53 Bn 4.47 Bn - 400,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 400,000.00
Mar 31, 2026 400,000.00
Dec 31, 2025 406,000.00
Dec 31, 2025 406,000.00
Sep 30, 2025 400,000.00
Sep 30, 2025 400,000.00
Jun 30, 2025 400,000.00
Jun 30, 2025 400,000.00
Mar 31, 2025 200,000.00
Mar 31, 2025 200,000.00
Dec 31, 2024 100,000.00
Dec 31, 2024 100,000.00
Sep 30, 2024 48,000.00
Sep 30, 2024 48,000.00
Jun 30, 2024 36,000.00
Jun 30, 2024 36,000.00
Mar 31, 2024 29,000.00
Mar 31, 2024 29,000.00